OS Therapies Incorporated
OSTX
$2.00
$0.189.89%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.97M | 2.02M | 957.30K | 1.10M | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.81M | 5.00M | 3.19M | 3.92M | 4.34M |
| Operating Income | -6.81M | -5.00M | -3.19M | -3.92M | -4.34M |
| Income Before Tax | -8.88M | -7.36M | -6.46M | -7.40M | -7.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.88 | -7.36 | -6.46 | -7.40 | -7.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.88M | -7.36M | -6.46M | -7.40M | -7.79M |
| EBIT | -6.81M | -5.00M | -3.19M | -3.92M | -4.34M |
| EBITDA | -6.81M | -5.00M | -3.18M | -3.92M | -4.34M |
| EPS Basic | -0.80 | -0.71 | -0.91 | -1.12 | -1.17 |
| Normalized Basic EPS | -0.44 | -0.44 | -0.56 | -0.69 | -0.72 |
| EPS Diluted | -0.80 | -0.71 | -0.91 | -1.12 | -1.17 |
| Normalized Diluted EPS | -0.44 | -0.44 | -0.56 | -0.69 | -0.72 |
| Average Basic Shares Outstanding | 55.06M | 43.98M | 33.42M | 32.77M | 31.57M |
| Average Diluted Shares Outstanding | 55.06M | 43.98M | 33.42M | 32.77M | 31.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |